Metabolomics-based biomarkers of probiotic efficacy in toxicological settings

IF 2.5 Q2 MULTIDISCIPLINARY SCIENCES

Beni-Suef University Journal of Basic and Applied Sciences Pub Date : 2024-09-04 DOI:10.1186/s43088-024-00546-1

Declan Ikechukwu Emegano, Dilek Battal, Kumsal Kocadal

{"title":"Metabolomics-based biomarkers of probiotic efficacy in toxicological settings","authors":"Declan Ikechukwu Emegano, Dilek Battal, Kumsal Kocadal","doi":"10.1186/s43088-024-00546-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Metabolomics is the study of metabolites in cells, tissues, live organisms, and biological fluids to elucidate their composition and possible roles. Metabolomics and its biomarkers have emerged as a powerful tool for evaluating the efficacy of probiotics in various pathological conditions, including toxicological settings. This review explores the use of metabolomics-based markers to assess the safety and efficacy of probiotics in toxicological settings.</p><h3>Result</h3><p>This review aims to determine biomarkers for measuring the effectiveness of probiotic therapies in toxicological contexts based on exposure, effects, susceptibility, prognostic, and therapeutic biomarkers. In this study, 1979 articles were systematically searched in PubMed (PM), Scopus (Sc), Google Scholar (GS), and Web of Science (WOS) between the years 2013 and 2023 inclusive using keywords, inclusion, and exclusion criteria. The result showed that 1439 human samples were used from 2013 to 2023 publications with the UK having the highest number of publications, data, and sample types in 2023. Again, the result showed most of the publications are on susceptibility-based biomarkers.</p><h3>Conclusion</h3><p>Metabolomics-based biomarkers may provide insight into metabolism-related alterations related to probiotic therapies while clarifying their biological mechanisms, especially in toxicology enabling specific probiotic therapy.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-024-00546-1","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beni-Suef University Journal of Basic and Applied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43088-024-00546-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Metabolomics is the study of metabolites in cells, tissues, live organisms, and biological fluids to elucidate their composition and possible roles. Metabolomics and its biomarkers have emerged as a powerful tool for evaluating the efficacy of probiotics in various pathological conditions, including toxicological settings. This review explores the use of metabolomics-based markers to assess the safety and efficacy of probiotics in toxicological settings.

Result

This review aims to determine biomarkers for measuring the effectiveness of probiotic therapies in toxicological contexts based on exposure, effects, susceptibility, prognostic, and therapeutic biomarkers. In this study, 1979 articles were systematically searched in PubMed (PM), Scopus (Sc), Google Scholar (GS), and Web of Science (WOS) between the years 2013 and 2023 inclusive using keywords, inclusion, and exclusion criteria. The result showed that 1439 human samples were used from 2013 to 2023 publications with the UK having the highest number of publications, data, and sample types in 2023. Again, the result showed most of the publications are on susceptibility-based biomarkers.

Conclusion

Metabolomics-based biomarkers may provide insight into metabolism-related alterations related to probiotic therapies while clarifying their biological mechanisms, especially in toxicology enabling specific probiotic therapy.

查看原文本刊更多论文

基于代谢组学的毒理学环境下益生菌功效生物标志物

背景代谢组学是对细胞、组织、活生物体和生物液体中的代谢物进行研究，以阐明其组成和可能的作用。代谢组学及其生物标志物已成为评估益生菌在各种病理条件（包括毒理学环境）下疗效的有力工具。本综述探讨了如何利用基于代谢组学的标志物来评估益生菌在毒理学环境中的安全性和有效性。结果本综述旨在根据暴露、效应、易感性、预后和治疗生物标志物来确定衡量益生菌疗法在毒理学环境中有效性的生物标志物。本研究采用关键词、纳入和排除标准，在 PubMed（PM）、Scopus（Sc）、Google Scholar（GS）和 Web of Science（WOS）中系统检索了 2013 年至 2023 年（含 2023 年）期间的 1979 篇文章。结果显示，在 2013 年至 2023 年的出版物中使用了 1439 份人类样本，其中英国在 2023 年的出版物、数据和样本类型数量最多。结论基于代谢组学的生物标志物可帮助人们深入了解与益生菌疗法相关的代谢相关改变，同时阐明其生物学机制，特别是在毒理学方面，使特定的益生菌疗法成为可能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Beni-Suef University Journal of Basic and Applied Sciences MULTIDISCIPLINARY SCIENCES-

CiteScore

2.60

自引率

0.00%

发文量

期刊介绍： Beni-Suef University Journal of Basic and Applied Sciences (BJBAS) is a peer-reviewed, open-access journal. This journal welcomes submissions of original research, literature reviews, and editorials in its respected fields of fundamental science, applied science (with a particular focus on the fields of applied nanotechnology and biotechnology), medical sciences, pharmaceutical sciences, and engineering. The multidisciplinary aspects of the journal encourage global collaboration between researchers in multiple fields and provide cross-disciplinary dissemination of findings.